Introduction

    Insulin with dextrose is an effective method to lower potassium levels quickly in acute hyperkalemia.

    Literature shows ranges of potassium reduction by 0.5-1.0 mEq after administration of a single dose.

    Patients with renal insufficiency and end stage renal disease (ESRD) have a higher incidence of

    hypoglycemia after treatment with insulin for hyperkalemia due to:

    o Reduced insulin clearance (prolonged insulin action)

    o Reduced hepatic glucose production

    o Reduced renal gluconeogenesis

    The appropriate dose of insulin to minimize hypoglycemic events when using for the treatment of

    hyperkalemia in patients with renal insufficiency is still debated.

Clinical Detail

ParameterDetail
MedicationInsulin (human regular)
MechanismCause an intracellular shift of potassium via exchange of sodium ions via the Na+/K+ ATPase pump
Dose5–10 units
Doses of 0.1 units/kg (max 10 units) have also been considered
AdministrationIV push
PK/PDOnset: 15–30 minutes for initial potassium lowering effects
Duration: 4–6 hours, prolonged duration in ESRD
Adverse EffectsHypoglycemia, hypokalemia, hypersensitivity
CompatibilityCan dilute in normal saline to increase volume for ease of administration
PearlsMust be given with dextrose (25g IV) to prevent hypoglycemia
– Some patients require repeated dextrose; rare exceptions for those already extremely hyperglycemic
The most common used product is regular human insulin given IV to ensure fast onset of potassium lowering effects and prevent variable absorption

Evidence

Author, YearDesign (Sample Size)Intervention & ComparisonOutcomes
Verdier et al., 2021Single center, retrospective (n=174)5 units vs 10 units IV regular insulin in ICU patientsHypoglycemia was more frequent with 10 unit vs 5 units of IV insulin (19.5 vs 9.2%, p=0.052)
No difference in rates of severe hypoglycemia or change in serum potassium
Moussavi et al., 2020Retrospective, observational (n=700)10 units vs <10 units IV regular insulinSignificantly lower frequency of hypoglycemia with lower insulin doses (11.2 vs 17.6%, p=0.008)
Greater reduction in serum potassium with insulin doses <10 units (mean reduction 0.94 vs 0.8, p=0.008)
Keeney et al., 2019Single center, retrospective (n=442)5 units vs 10 units IV regular insulinHypoglycemic events in patients with reduced eGFR were higher in patients receiving 10 units of insulin (17.4 vs 7.9%, p=0.02)
Similar potassium reductions in both groups
McNicholas et al., 2018Single center, retrospective (n=99)Evaluate hypoglycemia risk based on usage of hyperkalemia protocolSubgroup analysis showed trend towards hypoglycemia with higher doses of insulin in ESRD. (5 units: 28% vs 10 units: 54%)
LaRue et al., 2017Single center, retrospective (n=675)5 units vs 10 units IV regular insulinHypoglycemia was significantly increased in patients receiving 10 units of insulin (28.6 vs 19.5%, 95% CI −16.8% to −1.3%)
No significant difference in potassium decrease
Pierce et al., 2015Single center, retrospective (n=149)5 units vs. 10 units with low eGFRNo significant difference in hypoglycemia between those receiving 10 units or 5 units of insulin (19.7 vs 16.7%)
Apel et al., 2014Single center, retrospective (n=221)Hypoglycemia risk in patients receiving IV regular insulin (4–10 units) in patients with ESRD on HD90% of patients received 10 units of insulin
13% of patients experienced hypoglycemia (IV insulin doses not specified)
Patients who were not diabetic had a higher risk of hypoglycemic events (OR 2.3, 95% CI 1.0–5.1, p=0.05)
Schafers et al., 2012Single center, retrospective (n=89)Evaluated evidence of hypoglycemia in any patient receiving 5–10 units regular insulin61 patients had renal insufficiency (69%)
19 patients had hypoglycemia (21%)
15/19 patients who became hypoglycemic had renal insufficiency (79%)

Conclusions

    Hypoglycemia risk seems to be elevated in those patients with renal insufficiency, especially those

    who are insulin-naive

    Consideration should be made to lower the initial dose of IV insulin for patients with AKI or CKD

References

    LaRue, et al. Pharmacotherapy. 2017;37(12):1516-1522.

    Moussavi, et al. Crit Care Expl. 2020;2:e0092.

    Allon, et al. Kidney Int 1990;38 (5):869-72. 7.

    Allon, et al. Am J Kidney Dis 1996;28(4):508-14.

    Li, et al. Clin Kidney J. 2014;7:239-41.

    Schafers, et al. Journal of Hospital Medicine. 2012;7(3):239-42.

    Pierce, et al. Annals of Pharmacotherapy. 2015;49(12).1322-26.

    McNicholas, et al. Kidney Int Rep. 2018;3:328-36,

    Apel, et al. Clin Kidney J. 2014;7(2)248-50.

  • Keeney, et al. Am J Emerg Med. 2019; doi.org/10.1016/j.ajem.2019.158374
  • Insulin Human Regular. Micromedex [Electronic version].Greenwood Village, CO: Truven Health Analytics. Accessed 2020, February 8.
  • from http://www.micromedexsolutions.com/

  • Insulin human regular. Lexicomp [online database]. Hudson, OH. Woltes Kluwer Clinical Drug Information, Inc. Accessed 2020, February 8.
  • http://www.online.lexi.com

  • Verdier, et al. Aust Crit Care. 2021;S1036-7314(21)00070-9.
Tags:hyperkalemia insulin renal insufficiency hypoglycemia